Ditophal

Ditophal is an orally active thiol ester anti-tuberculosis and anti-leprosy agent. Ditophal combats Mycobacterium tuberculosis infections in subcutaneous and intracerebral sites in guinea pigs, including isoniazid (HY-B0329)-resistant strains. Ditophal alters the staining characteristics of Mycobacterium leprae and reduces the bacterial index of leprosy. Ditophal causes ulcers at the injection site when administered subcutaneously to guinea pigs at high doses. Ditophal can be used in the research of tuberculosis and leprosy^[1][2]. In Vivo:Ditophal (100-200 mg/kg; p.o.; twice daily; for 90 consecutive days) reduces the organ severity score of tuberculosis and prolongs the survival time of guinea pigs subcutaneously infected with Mycobacterium tuberculosis^[1].
Ditophal (10-50 mg/kg; subcutaneous injection; daily or weekly; for 120 consecutive days) reduces the tuberculosis organ severity score and prolongs the survival time of guinea pigs subcutaneously infected with Mycobacterium tuberculosis^[1].
Ditophal (100-200 mg/kg; p.o.; twice daily; for 4 consecutive weeks) prolongs the average survival time of guinea pigs with intracerebral Mycobacterium tuberculosis infection, and the 100 mg/kg dose group shows a longer average survival time of up to 35.0 days^[1].